Sfoglia per Autore
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis
2021 Rizzo A.; Mollica V.; Santoni M.; Rosellini M.; Marchetti A.; Ricci A.D.; Grilli G.; Greco A.; Montironi R.; Ardizzoni A.; Massari F.
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review
2021 Rizzo A.; Mollica V.; Dall'Olio F.G.; Ricci A.D.; Maggio I.; Marchetti A.; Rosellini M.; Santoni M.; Ardizzoni A.; Massari F.
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials
2021 Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Rosellini M.; Marchetti A.; Montironi R.; Ardizzoni A.; Massari F.
Nivolumab: an investigational agent for the treatment of biliary tract cancer
2021 Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G.
Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies
2021 Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G.
Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Brandi G.
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue
2021 Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G.
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
2021 Rizzo A.; Ricci A.D.; Brandi G.
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Brandi G.
Recent advances of immunotherapy for biliary tract cancer
2021 Rizzo A.; Ricci A.D.; Brandi G.
Hacking pancreatic cancer: Present and future of personalized medicine
2021 Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Marco M.; Palloni A.; Brandi G.
Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities?
2021 Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G.
Toward personalized therapy for cholangiocarcinoma: new insights and challenges
2021 Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G.
Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?
2021 Rizzo A.; Ricci A.D.; Brandi G.
Bone targeting agents in patients with metastatic prostate cancer: State of the art
2021 Mollica V.; Rizzo A.; Rosellini M.; Marchetti A.; Ricci A.D.; Cimadamore A.; Scarpelli M.; Bonucci C.; Andrini E.; Errani C.; Santoni M.; Montironi R.; Massari F.
In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)”
2021 Ricci A.D.; Rizzo A.; Brandi G.
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
2021 Rizzo A.; Ricci A.D.; Gadaleta-Caldarola G.; Brandi G.
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2021 Rizzo A.; Ricci A.D.; Brandi G.
Novel HER2-directed treatments in advanced gastric carcinoma: Another paradigm shift?
2021 Ricci A.D.; Rizzo A.; Llimpe F.L.R.; Fabio F.D.; De Biase D.; Rihawi K.
Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma
2021 Rizzo A.; Ricci A.D.; Brandi G.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile